Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

19 Jul 2017

Abstract excerpt

We conducted a first-in-human study of intravenous delivery of a single dose of autologous T cells redirected to the epidermal growth factor receptor variant III (EGFRvIII) mutation by a chimeric antigen receptor (CAR). We report our findings on the first 10 recurrent glioblastoma (GBM) patients treated. We found that manufacturing and infusion of CAR-modified T cell (CART)-EGFRvIII cells are feasible and safe,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Nanowire Synthesis and Applications
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28724573
DOI: 10.1126/scitranslmed.aaa0984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaPMID 28724573Read ↗

Phase I study of repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab in patients with newly diagnosed, MGMT-unmethylated glioblastomaSemantic proximity Read ↗

High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic IsoformsSemantic proximity Read ↗

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in GlioblastomaSemantic proximity Read ↗

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escapeSemantic proximity Read ↗

CAR T cell therapy for glioblastoma: A review of the first decade of clinical trialsSemantic proximity Read ↗

Application of blood brain barrier models in pre-clinical assessment of glioblastoma- targeting CAR-T based immunotherapiesSemantic proximity Read ↗

A Bi-Specific T Cell-Engaging Antibody Triggers Protective Immune Memory and Glioma Microenvironment Remodeling in Immune Competent Preclinical ModelsSemantic proximity Read ↗

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.Semantic proximity Read ↗

Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cellsSemantic proximity Read ↗

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic miceSemantic proximity Read ↗

Tumor-responsive, multifunctional CAR-NK cells cooperate with impaired autophagy to infiltrate and target glioblastomaSemantic proximity Read ↗

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.